This came to my attention a while back, but for some reason got buried in my inbox. So sorry Laura!
Two new oncology tests — classifying metastatic cancer and identifying patients with estrogen receptor positive (ER+) breast cancer who are at high risk of recurrence as well as unlikely to respond favorably to standard adjuvant endocrine therapy — from AviaraDx, Inc. are now state-approved in New York.
The tests, based on proprietary AviaraDx molecular technologies, are New York state-approved and available through the company’s CAP-certified CLIA laboratory. Both can utilize small formalin-fixed and paraffin-embedded (FFPE) tissue samples easily available …read more

CBD, a compound found in Cannabis Sativa (or marijuana) may prove to be effective in helping stop the spread of breast cancer cells throughout the body.
Such were the findings by scientists at the California Pacific Medical Center Research Institute. CBD could be the first non-toxic agent to show promise in treating metastatic forms of breast cancer.
According to Sean D. McAllister, Ph.D., a cancer researcher at CPMCRI and the lead author of the study:
“Right now we have a limited range of options in treating aggressive forms of cancer. Those treatments, such as chemotherapy, can be effective but they can also be …read more

Cancer is said to be metastatic once cancer in one body spreads to other body parts. In lay man’s term, the spreading of cancer to other locations.
When cancer becomes metastatic, it becomes an advanced stage cancer that is most often difficult to treat because the cancer becomes unresponsive to typical treatment.
Like metastatic breast cancer that becomes unresponsive to two chemotherapy treatments that include an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel).
This is where new anti-cancer treatment Ixempra comes in that is recently approved by the FDA.
The approval of Ixempra includes the following:

for use …read more

A product of GlaxoSmithKile Plc – TYKERB® (lapatinib) – has recently been approved by the USFDA, in combination with Xeloda® (capecitabine), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
TYKERB® (a pdf file) – a small molecule that inhibits the tyrosine kinase components of the EGFR (ErbB1) and HER2 (ErbB2) receptors – is the first targeted, once-daily oral treatment option for the abovementioned patient population.
This approval reflects more than 16 years of research, including more than 60 clinical trials and investigator-initiated …read more